Brentuximab vedotin (Adcetris®) for CD30+ Hodgkins lymphoma. HTA ID: 19058

Assessment Status NCPE Assessment Process Complete
HTA ID 19058
Drug Brentuximab vedotin
Brand Adcetris®
Indication Treatment of adult patients with CD30+ Hodgkin’s lymphoma at increased risk of relapse or progression following autologous stem cell transplant.
Assessment Process
Rapid review commissioned 30/12/2019
Rapid review completed 29/01/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brentuximab vedotin compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 05/02/2020
Pre-submission consultation with Applicant 19/05/2020
Full submission received from Applicant 11/01/2021
Preliminary review sent to Applicant 12/07/2021
NCPE assessment re-commenced 06/08/2021
Factual accuracy sent to Applicant 24/09/2021
NCPE assessment re-commenced 30/09/2021
NCPE assessment completed 22/10/2021
NCPE assessment outcome The NCPE recommends that brentuximab vedotin be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medicinal Goods) Act 2013.

Technical Summary

Plain English Summary

The HSE has approved reimbursement following confidential price negotiations, December 2022.